Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 2Tumor-Agnostic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Glioblastoma 1Colonic Neoplasms 1Astrocytoma 1Advanced Breast Carcinoma 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × TVB-2640 × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

NCT05743621 2025-11-21

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05118776 2024-10-31

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Ascletis Pharma Inc

Phase 3 Active not recruiting
136 enrolled
CNS

Glioblastoma

NCT02980029 2024-10-22

TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

University of Kentucky

Phase 1 Terminated
23 enrolled
Gastrointestinal

Colonic Neoplasms

NCT03032484 2023-06-15

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
25 enrolled 9 charts
CNS

Astrocytoma

NCT02223247 2017-08-14

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Sagimet Biosciences Inc.

Phase 1 Completed
180 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡